Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Is Tirzepatide the Same as Mounjaro? One Drug, Three Names

Is tirzepatide the same as Mounjaro? Yes, it is. Mounjaro is a brand name, and tirzepatide is the medicine inside it, as well as inside a second brand, Zepbound. So one drug carries three names: one generic name and two brand names, both from Eli Lilly.

This page answers a naming question: how one generic name relates to its brand names, and what the official records prove. It is not a product comparison of the two brands. It walks through the FDA records: how one molecule came to have two US labels, what each label covers as of 20 November 2026, and why Europe sells it under one name.

On this page

What are the three names for tirzepatide?

One generic name and two brand names. Tirzepatide is the generic name, and both FDA labels print it in parentheses after the brand. FDA also calls tirzepatide the active ingredient, and it calls Mounjaro and Zepbound trade names. Think of one song released on two albums: the music is the same, the cover is not.

Tirzepatide and its two US brand names, from the FDA labels and Drugs@FDA, checked 20 November 2026.
NameWhat kind of nameWhoseFDA record
TirzepatideGeneric name, which FDA calls the active ingredientThe molecule itself, in both brandsPrinted in parentheses on both US labels
MounjaroBrand name, which FDA calls a trade nameEli LillyNDA 215866, won FDA approval 13 May 2022
ZepboundBrand name, which FDA calls a trade nameEli LillyNDA 217806, won FDA approval 8 November 2023

When Zepbound won FDA approval in November 2023, the FDA news release said the active ingredient was already approved under the trade name Mounjaro. Both are prescription medicines, and as of 20 November 2026 openFDA lists only these two tirzepatide applications, each with Eli Lilly as the sponsor.

Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); FDA news release on Zepbound, 8 Nov 2023; Tirzepatide applications, Drugs@FDA (openFDA)

How do we know it is the same molecule?

The two labels describe it in matching terms, and FDA gives it one substance code. Picture one key, cut once, then hung on two keyrings with different name tags. Here is what the records show, side by side.

Identity checks for tirzepatide in Mounjaro and Zepbound, from both US labels and their openFDA records.
CheckWhat the records say
Chemical descriptionWord for word the same in both labels: built on the GIP sequence, with Aib at positions 2 and 13 and a fatty side chain at lysine 20
Molecular weight4,813.53 Da in both labels
FormulaC225H348N48O68 in both labels
FDA substance code (UNII)OYN3CCI6QE for the tirzepatide in both brands

This page stays with names and records. What the molecule does in the body is on our episode page about how tirzepatide works.

Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed)

How did one molecule end up with two US names?

Through two separate FDA applications, years apart. On 13 May 2022, Mounjaro won FDA approval to help adults who have type 2 diabetes control their blood sugar, alongside diet and exercise. FDA classed it as a new molecular entity, meaning tirzepatide was a new molecule then. Weight fell more than with the comparison drugs in those trials, yet Lilly said at launch that Mounjaro was not meant for weight loss.

Lilly says the weight approval rested on two phase 3 trials, SURMOUNT-1 and SURMOUNT-2. In SURMOUNT-1, 2,539 adults without diabetes got tirzepatide or placebo for 72 weeks, and average weight change ran from about 15 to 21 percent down in the three tirzepatide groups, against about 3 percent on placebo. Those are trial averages, not a promise for any one person.

On 8 November 2023, the same molecule won FDA approval again, as Zepbound, for chronic weight management. FDA classed that first Zepbound application as Type 10: a new use filed as its own application and not folded into Mounjaro's. That is how one molecule came to carry two US brand names, each with its own application and label.

What FDA records do not show is why Lilly chose a second name. No primary source we opened gives that reason, so this page does not guess at one.

Sources: FDA bulletin on Mounjaro, 13 May 2022; Tirzepatide applications, Drugs@FDA (openFDA); Lilly news release on Mounjaro, May 2022; Lilly news release on Zepbound, Nov 2023; SURMOUNT-1, NEJM 2022 (PMID 35658024); FDA news release on Zepbound, 8 Nov 2023

Does Europe use the Zepbound name?

No. The European Medicines Agency lists one tirzepatide brand, Mounjaro, which received EU-wide authorisation on 15 September 2022. In the EU, Mounjaro is used for type 2 diabetes and also, with diet and physical activity, to help adults lose weight and keep it off. EMA records hold no product called Zepbound.

So the second name is a US story. Someone reading a European leaflet for Mounjaro may see a weight use that the US Mounjaro label does not have.

Sources: EMA overview of Mounjaro

How have the two labels changed since 2022?

Each brand has gained uses on its own file, and the two lists still do not overlap. An indication is a use written on a drug's label, a bit like the list of doors printed on each keyring's tag. This timeline shows when each record changed, as of 20 November 2026.

Tirzepatide record timeline, from Drugs@FDA, the two US labels (effective 27 and 28 August 2026), FDA releases and EMA.
DateRecordWhat changed
13 May 2022Mounjaro, NDA 215866First approval, for type 2 diabetes blood sugar control in adults. FDA classed tirzepatide as a new molecular entity
15 Sep 2022Mounjaro, EUEU-wide authorisation. As of the August 2026 EMA overview, this one brand covers type 2 diabetes and weight management
8 Nov 2023Zepbound, NDA 217806First approval, for chronic weight management. FDA classed it Type 10, a new use filed as its own application
20 Dec 2024ZepboundObstructive sleep apnea in adults with obesity added
Dec 2025MounjaroChildren 10 and older with type 2 diabetes added
Aug 2026MounjaroHeart attack, stroke and heart death risk use added, for adults with type 2 diabetes at high heart risk

The Mounjaro heart use rests on SURPASS-CVOT, a human trial of 13,299 people with type 2 diabetes and heart disease. It compared Mounjaro with Trulicity, an older Lilly diabetes drug. For heart attack, stroke or heart death counted together, Mounjaro was non-inferior to Trulicity, meaning not worse by a set margin, but it was not shown to be better.

Today the Mounjaro label lists no weight loss use, and Zepbound is not approved for children. In its sleep apnea release, FDA described Zepbound as the first drug option for certain people with that condition.

Sources: Tirzepatide applications, Drugs@FDA (openFDA); Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Lilly news release on the heart risk approval, 2026; Trulicity records, Drugs@FDA (openFDA); FDA news release on sleep apnea, 20 Dec 2024; EMA overview of Mounjaro

What do the two brands share on their labels?

Both labels carry the same boxed warning: tirzepatide caused thyroid C-cell tumors in rats. That is animal data, and both labels say it is unknown whether it happens in humans. Both list the same reasons not to use it: medullary thyroid carcinoma in the person or in their family, MEN 2, or a known serious allergy to tirzepatide or the other ingredients. The full side effect picture is on our page about Mounjaro side effects.

Compounded tirzepatide is not a third brand name: openFDA lists only the two Lilly applications. How compounded versions differ is covered on our page on compounded tirzepatide vs Zepbound.

Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Tirzepatide applications, Drugs@FDA (openFDA)

What else do people ask about tirzepatide and Mounjaro?

Is tirzepatide the same as Mounjaro?+

Yes, they are one medicine. Tirzepatide is the generic name of what is inside Mounjaro. Mounjaro is the brand name Eli Lilly uses for it in the US for type 2 diabetes and heart event risk.

Is Zepbound the same drug as Mounjaro?+

Same molecule, different label. Both contain tirzepatide, and both US labels give it the same chemical description, weight and formula. Each brand has its own FDA application and its own approved uses.

Why does tirzepatide have two brand names in the US?+

FDA records show how, not why. FDA classed the first Zepbound application as Type 10, a new use filed as its own application rather than added to Mounjaro. The records do not give the reason Lilly chose a second name.

Is Mounjaro approved for weight loss?+

Not in the US. As of 20 November 2026, the Mounjaro label lists no weight loss use. Weight reduction is on the Zepbound label. In the EU, the one brand Mounjaro covers both type 2 diabetes and weight management.

Who makes tirzepatide?+

Eli Lilly. As of 20 November 2026, openFDA lists exactly two tirzepatide applications, Mounjaro and Zepbound, and Eli Lilly is the sponsor of both.

Do Mounjaro and Zepbound share the same warning?+

Yes. Both labels carry a boxed warning that tirzepatide caused thyroid C-cell tumors in rats, and both say it is unknown whether this happens in humans. They list the same reasons not to use it.

Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Tirzepatide applications, Drugs@FDA (openFDA); EMA overview of Mounjaro

So is tirzepatide the same as Mounjaro?

Yes, by every record above. It is one molecule sold under two US brand names, both from Eli Lilly. The Mounjaro label covers type 2 diabetes and heart event risk in some high risk adults with it. The Zepbound label covers weight reduction and sleep apnea. In Europe, the one brand is Mounjaro.

The Molecule Mechanics channel explains molecules in short animated episodes, and lists its sources under each one. We checked the two US labels, Drugs@FDA, the FDA and EMA pages, the Lilly releases and the SURMOUNT-1 report on 20 November 2026, as our medical review policy asks.

Spotted an error? Our corrections policy says how to report it.

Sources: Mounjaro US label, effective 27 Aug 2026 (DailyMed); Zepbound US label, effective 28 Aug 2026 (DailyMed); Tirzepatide applications, Drugs@FDA (openFDA); EMA overview of Mounjaro

This page is about names and regulatory records only, and it gives no advice. Each section lists the records it used at its end.

Sources

  1. 1.Mounjaro (tirzepatide) US prescribing information, Eli Lilly, set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 27 August 2026, read again in openFDA for this page on 20 November 2026: generic name in parentheses; chemical description, molecular weight 4,813.53 Da and formula C225H348N48O68; substance code UNII OYN3CCI6QE; uses for type 2 diabetes from age 10 (12/2025) and for cutting major heart event risk when type 2 diabetes comes with high heart risk (08/2026); SURPASS-CVOT with 13,299 people, non-inferior to dulaglutide, superiority not established; the boxed warning and contraindications.
  2. 2.Zepbound (tirzepatide) US prescribing information, Eli Lilly, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 28 August 2026: the same chemical description, weight, formula and UNII; uses for long term weight reduction and for obstructive sleep apnea, each paired with diet and activity; not established in children.
  3. 3.Drugs@FDA via openFDA, tirzepatide: NDA 215866 (Mounjaro) and NDA 217806 (Zepbound), both Eli Lilly and Co, both prescription; Mounjaro first approved on 13 May 2022 and classed as a new molecular entity (Type 1); Zepbound original approval 8 November 2023, Type 10, a new indication submitted as a distinct NDA, not consolidated; Zepbound efficacy supplement of 20 December 2024.
  4. 4.FDA bulletin, 13 May 2022: Mounjaro won FDA approval as an add-on to diet and exercise for blood sugar in type 2 diabetes in adults, and called it a first-in-class medicine that activates both the GLP-1 and GIP receptors; priority review.
  5. 5.FDA news release, 8 November 2023: Zepbound won FDA approval for chronic weight management, and FDA said tirzepatide, its active ingredient, is already approved under the trade name Mounjaro.
  6. 6.FDA news release, 20 December 2024: Zepbound won FDA approval to treat obstructive sleep apnea in adults with obesity when it is moderate to severe.
  7. 7.Eli Lilly news release, May 2022: Mounjaro was not indicated for weight loss, though weight fell more than with comparison drugs in the trials. Company source, used only for this statement.
  8. 8.Eli Lilly news release, November 2023: the Zepbound approval was based on the phase 3 SURMOUNT-1 and SURMOUNT-2 trials. Company source.
  9. 9.Eli Lilly news release on the Mounjaro heart risk approval, 2026: SURPASS-CVOT hazard ratio 0.92 (95.3% CI 0.83 to 1.01) for heart attack, stroke or cardiovascular death against dulaglutide. Company source; the label states superiority was not established.
  10. 10.Jastreboff AM and colleagues, SURMOUNT-1, N Engl J Med 2022;387:205-216, PMID 35658024: 2,539 adults without diabetes who had obesity, or excess weight with a related complication, on tirzepatide or placebo for 72 weeks; average weight change between -15.0% and -20.9% in the three tirzepatide arms, and -3.1% on placebo.
  11. 11.European Medicines Agency, Mounjaro overview, last updated 18 August 2026: one brand, Mounjaro, used for type 2 diabetes and, with diet and physical activity, for weight management in adults; EU marketing authorisation on 15 September 2022; no separate Zepbound product in EMA records.
  12. 12.Drugs@FDA and label records for Trulicity (dulaglutide), via openFDA, checked 20 November 2026: an Eli Lilly prescription product under BLA 125469, first approved 18 September 2014, for type 2 diabetes.